Results 81 to 90 of about 13,380 (189)

Atrophic Papulosis: A Systematic Review of Pediatric Cases

Pediatric Dermatology, EarlyView.
ABSTRACT Background Atrophic papulosis is a rare occlusive vasculopathy that can present with isolated cutaneous disease or with systemic involvement. Pediatric cases are uncommon, and existing reports are heterogeneous, limiting understanding of disease patterns, timing of organ involvement, and outcomes.
Ou Jia Emilie Wang, Alennie Lopez, Renee Gabrielle Fajardo, Richard I. Crawford, Joseph M. Lam   +4 more
wiley   +1 more source

Eculizumab [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

Transfusion, EarlyView.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman, Meghana Vivek, Rida Hasan, Siobán Keel, Laura Connelly‐Smith   +4 more
wiley   +1 more source

Eculizumab versus rituximab in generalised myasthenia gravis

, 2022
OBJECTIVE: Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse.
Regner-Nelke, Liesa, Arat, Ercan, Mergenthaler, Philipp, Vielhaber, Stefan, Stascheit, Frauke, Pawlitzki, Marc, Totzeck, Andreas, Nelke, Christopher, Schroeter, Christina B, Huntemann, Niklas, Öztürk, Menekse, Hagenacker, Tim, Melzer, Nico, Schreiber, Stefanie, Gassa, Asmae, Schroeter, Michael, Meisel, Andreas, Berger, Benjamin, Ruck, Tobias, Hartung, Hans-Peter, Wiendl, Heinz, Stetefeld, Henning, Meuth, Sven G   +22 more
core   +1 more source

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment

Blood Advances
: In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality.
Austin G. Kulasekararaj, Jong Wook Lee, Christopher J. Patriquin, Caroline I. Piatek, Alexander Röth, Wilma Barcellini, Robert A. Brodsky, Jun-ichi Nishimura, Ji Yu, Mohammed Mahdi, Régis Peffault de Latour   +10 more
doaj   +1 more source

Clonal Dynamics of GPI‐Deficient Cells in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Follow‐Up Analysis

European Journal of Haematology, Volume 117, Issue 6, Page 1583-1592, December 2026.
ABSTRACT This retrospective, single‐center study aimed to characterize clonal dynamics of GPI‐deficient cells in patients with paroxysmal nocturnal hemoglobinuria (PNH) or PNH/aplastic anemia (AA) syndrome using multiparameter flow cytometry including FLAER.
Sandra M. Frey, Friederike Poppenborg, Ute Schmücker, Nicole Preising, H. Christian Reinhardt, Alexander Röth, Ferras Alashkar   +6 more
wiley   +1 more source

Safety and Effectiveness of Eculizumab throughout Three Pregnancies in a Patient with Refractory Generalized Myasthenia Gravis: A Case Report

Case Reports in Neurology
We describe maternal and fetal outcomes in a patient who had three successful pregnancies while being treated with eculizumab for AChR+ gMG.
Nadia Khalil, Claudia Guerra Hernandez, Jerrica Farias, Kathleen Murray, Niraja Suresh, Clifton Gooch, Tuan H. Vu   +6 more
doaj   +1 more source

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

PLoS ONE, 2020
BackgroundEculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden.
John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, Saskia M C Langemeijer, Susan Yount, F Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, Christa Martens, Amy Sparling, Kimberly A Webster, David Cella, Ioannis Tomazos, Masayo Ogawa, Caroline I Piatek, Richard Wells, Flore Sicre de Fontbrune, Alexander Röth, Lindsay Mitchell, Anita Hill, Karen Kaiser   +19 more
doaj   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang, Siwen Wu, Yusi Wang, Die Hu, Li Yang   +4 more
wiley   +1 more source

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study

Health Technology Assessment
Background Atypical haemolytic uraemic syndrome is a rare disease (incidence: 0.4 cases per million per year) which, without treatment, is associated with high morbidity and mortality.
Andrew Bryant, Jan Lecouturier, Giovany Orozco-Leal, Vicky Brocklebank, Sonya Carnell, Thomas J Chadwick, Sarah Dunn, Sally A Johnson, David Kavanagh, Ciara A Kennedy, Michal Malina, Emma K Montgomery, Colin R Muirhead, Yemi Oluboyede, Luke Vale, Chris Weetman, Edwin Kwan Soon Wong, Len Woodward, Neil S Sheerin   +18 more
doaj   +1 more source